Mark Pflug~~Eric Swedenburg~~Sara Razi~~Preston Miller~~Nicholas Ingros~~Lori Lesser~~Vanessa Burrows
January 24, 2026
Simpson Thacher Represents CSL Behring in Formation of CoVIg-19 Plasma Alliance

1 min
AI-made summary
- CSL Behring, represented by Simpson Thacher, has co-founded the CoVIg-19 Plasma Alliance with Takeda and other major plasma companies, including Biotest, LFB, and Octapharma
- The Alliance aims to develop CoVIg-19, a plasma-derived therapy intended to treat COVID-19 patients at the early stages of illness
- The initiative seeks to support national governments in combating the pandemic by producing an unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine.
The Firm is representing CSL Behring in connection with the formation of the CoVIg-19 Plasma Alliance, an unprecedented partnership of the world’s leading plasma companies, spanning plasma collection, development, production and distribution. CSL Behring and Takeda are the founders of the Alliance. In addition to CSL Behring, the Plasma Alliance’s members include Biotest, LFB, Octapharma, Takeda and several other companies.~~The Plasma Alliance is seeking to develop CoVIg-19, a potential plasma-derived therapy for treating COVID-19. The Plasma Alliance will work toward developing the unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals at the onset of clinical progression, but prior to development of serious complications, and to support national governments in their efforts to fight the current pandemic.~~The Simpson Thacher team includes Mark Pflug, Eric Swedenberg and Yui Hirohashi (M&A); Sara Razi, John Goheen, Preston Miller and Nicholas Ingros (Antitrust); Lori Lesser (Intellectual Property); and Vanessa Burrows (Healthcare).
Article Author
Mark Pflug~~Eric Swedenburg~~Sara Razi~~Preston Miller~~Nicholas Ingros~~Lori Lesser~~Vanessa Burrows
The Sponsor
